Beclin-1 F121A-Mediated Longevity Depends on Reducing mtDNA Heteroplasmy Below a Tissue-Specific Threshold

Ingrid Addo (DPhil)· Mar 11, 2026

Mechanism: The Beclin-1 F121A mutation disrupts BCL-2 binding, enhancing selective mitophagy to clear mitochondria with pathogenic mtDNA heteroplasmy. Readout: Readout: This prevents NF-κB activation and inflammation, correlating with significantly reduced tissue heteroplasmy and extended lifespan.

Hypothesis: The lifespan and healthspan extension observed in Beclin-1 F121A mice is primarily mediated through reduced accumulation of mtDNA heteroplasmy in post-mitotic tissues. Disrupting BCL-2/Beclin-1 binding enhances selective mitophagy, preferentially clearing mitochondria harboring pathogenic heteroplasms before they reach a tissue-specific threshold that triggers NF-κB-mediated inflammation and metabolic dysfunction.

Mechanistic Framework

A key question remains unanswered: does the well-documented lifespan extension in Beclin-1 F121A mice correlate with suppressed heteroplasmy accumulation rather than general autophagy enhancement? The mechanism ties together several observations.

First, NF-κB-driven BCL-2 upregulation with age creates a tissue-specific autophagy bottleneck that hits mitochondrial quality control hard [1]. Since mitochondria carry their own genome—and heteroplasmy represents a cell-intrinsic metric of mitochondrial genetic damage—age-related autophagy suppression would disproportionately impact mtDNA quality relative to nuclear-encoded proteins. The result is damaged mitochondria accumulating even when nuclear protein turnover is otherwise adequate.

Second, parkin-dependent mitophagy accounts for roughly a quarter of mitochondrial protein turnover [2], indicating considerable selective pressure on mitochondrial quality control pathways. The Beclin-1 F121A mutation may boost this selective clearance beyond basal rates, allowing preferential removal of mitochondria with high heteroplasmy before they trigger inflammatory signaling.

Third, high mtDNA heteroplasmy independently induces aging phenotypes, including altered metabolism and accelerated epigenetic age in cells with identical nuclear genomes [3]. This shows that mtDNA quality deterioration can drive aging independent of nuclear genome effects, supporting the idea that reversing heteroplasmy accumulation could itself extend lifespan.

Testable Predictions

Beclin-1 F121A mice will exhibit significantly lower tissue heteroplasmy levels—measured via deep sequencing of mtDNA from brain, heart, and skeletal muscle—compared to wild-type littermates at 18-24 months of age, despite identical nuclear genomes.
Crossing Beclin-1 F121A mice with mice engineered to carry pre-existing high heteroplasmy (via germline transmission of pathogenic mtDNA mutations) will result in offspring with intermediate lifespan extension, demonstrating that heteroplasmy load modulates the magnitude of autophagy-mediated longevity.
Tissue-specific heteroplasmy thresholds will correlate with tissue-specific aging phenotypes: tissues exceeding a critical heteroplasmy burden (estimated at 30-35%) will display NF-κB activation, inflammatory cytokine expression, and metabolic dysfunction proportional to heteroplasmy load rather than chronological age.

Falsifiability Criteria

This hypothesis is falsified if: (a) Beclin-1 F121A mice show no reduction in tissue heteroplasmy despite extended lifespan, indicating the mechanism is independent of mtDNA quality; (b) Lifespan extension persists even when heteroplasmy is artificially maintained at high levels through genetic manipulation; or (c) Nuclear DNA damage markers correlate better with longevity outcomes than mtDNA heteroplasmy in these models.

Novel Contribution

Previous work established that mtDNA damage accumulates with age [4] and that autophagy enhancement extends lifespan [5], but no study has directly linked these observations causally. This hypothesis provides a testable framework connecting the mitochondrial genome as a proximal driver of aging to the well-validated Beclin-1 longevity axis. If supported, this would reposition mtDNA quality control—not nuclear genome integrity—as the primary therapeutic target for interventions targeting the autophagy-aging relationship.

[1] https://pubmed.ncbi.nlm.nih.gov/23220384/ [2] https://doi.org/10.1080/15548627.2019.1586258 [3] https://pubmed.ncbi.nlm.nih.gov/39680477/ [4] https://pmc.ncbi.nlm.nih.gov/articles/PMC5697406/ [5] https://pubmed.ncbi.nlm.nih.gov/29849149/